Abstract
Objectives To determine whether UVA exposure might be associated with COVID-19 deaths
Design Ecological model and meta-analysis
Setting 2,474 counties of the contiguous USA, 6,755 municipalities in Italy, 6,274 areas in England. Data were collected during their ‘Vitamin D winter’ (monthly mean UVvitd of under 165 KJ/m2) from Jan to April 2020.
Participants (instead of patients or subjects) The ‘at-risk’ population is the total county population, with measures to incorporate spatial infection into the model. The model is adjusted for: age, ethnicity, socioeconomic deprivation, long term PM2.5, and UV weighted by the vitamin D action spectrum.
Main outcome measures We derive UVA measures for each area and estimate their relationship with COVID-19 mortality with a random effect for States, in a multilevel zero-inflated negative binomial model. In the USA and England death certificates had to record COVID-19. In Italy excess deaths in 2020 over expected from 2015-19.
Data sources Satellite derived mean daily UVA dataset from Japan Aerospace Exploration Agency. Data on deaths compiled by Center for Disease Control (USA), Office for National Statistics (England) and Italian Institute of Statistics.
Results Daily mean UVA (January-April 2020) varied between 450 to 1,000 KJ/m2 across the three countries. Our fully adjusted model showed an inverse correlation between UVA and COVID-19 mortality with a Mortality Risk Ratio (MRR) of 0.73 (0.62 to 0.87)per 100KJ/m2 increase UVA in the USA, 0.81 (0.71 to 0.93) in Italy and 0.51 (0.39 to 0.66) in England. Pooled MRR was 0.68 (0.53 to 0.66).
Conclusions Our analysis, replicated in 3 independent national datasets, suggests ambient UVA exposure is associated with lower COVID-19 specific mortality. This effect is independent of vitamin D, as it occurred at irradiances below that likely to induce significant cutaneous vitamin D3 synthesis.
Causal interpretations must be made cautiously in observational studies. Nonetheless this study suggests strategies for reduction of COVID-19 mortality
Competing Interest Statement
Dr Weller is a director of Relaxsol
Funding Statement
No external funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used publicly available datasets and there was no link to individual patients
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data Availability The UVA estimates were developed by JAXA, with MODIS data provided by NASA GSFC, and available from ftp://apollo.eorc.jaxa.jp/pub/JASMES/Global_05km/. The long term UVvitd estimates were developed by NCAR and available from https://www2.acom.ucar.edu/modeling/tuv-download. The USA COVID-19 death and county level indicators of population, socioeconomic and environmental data (PM2.5 and temperature) were developed previously by Xiao Wu et al., and are available here: https://github.com/wxwx1993/PM_COVID. Code Availability The code and data to reproduce the current study is held at https://github.com/markocherrie/COVID19_UVA.
ftp://apollo.eorc.jaxa.jp/pub/JASMES/Global_05km/
